Pfizer signs agreement to allow broader access to its Covid-19 pill
Pfizer has signed a licensing agreement in order to allow broader global access towards its Covid-19 treatment pill.
The agreement was made with the a UN-backed public health organization called “Medicines Patent Pool”. This will give allowance to generic manufacturers who will then make the pill widely available in 95 middle-income countries covering 53% of the world’s population, according to the company’s statement.
The pill is called PF-07321332 or Paxlovid, and it is to be given in combination with an older antiviral drug called ritonavir.
Pfizer announced topline results from its trial saying that an interim analysis , done before the trial was scheduled to end showed an 89% reduction in the risk of hospitalization or death from Covid-19 among people given the drug within the first three days of symptom onset.
According to Pfizer’s statement , the company will profit in the sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
Stay tuned to Baaghi TV for latest news and updates!
